Skip to main content

Table 1 Patient characteristics

From: Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer

Cohort

Case

Age/gender

Diagnosis

Disease stage

ECOG/PS

Prior treatment

Combined treatment (chemotherapy)

NK cell administration

1

1

57/M

Rectal cancer

Recurrent

1

Surgery, chemotherapy

None

Excluded from triala

2

74/F

Rectal cancer

Recurrent

0

Surgery, chemotherapy

S-1

Excluded from triala

3

61/M

Esophageal cancer

Metastatic

2

Chemotherapy, radiation therapy

None

Complete

4

62/M

Gastric cancer

Recurrent

2

Surgery, chemotherapy

S-1

Incomplete (2 times)

5

72/M

Esophageal cancer

Recurrent

0

Surgery, chemotherapy

None

Complete

6

73/M

Colon cancer

Recurrent

0

Surgery, chemotherapy

None

Complete

7

66/M

Gastric cancer

Metastatic

0

Chemotherapy

None

Complete

2

8

62/M

Esophageal cancer

Recurrent

0

Surgery, chemotherapy, radiation therapy

None

Complete

9

65/M

Colon cancer

Metastatic

0

Chemotherapy

S-1

Complete

10

67/M

Esophageal cancer

Metastatic

2

Chemotherapy, radiation therapy

None

Incomplete (2 times)

11

69/M

Gastric cancer

Metastatic

0

Chemotherapy

None

Complete

3

12

60/M

Colon cancer

Recurrent

0

Surgery, chemotherapy

None

Complete

13

78/F

Rectal cancer

Recurrent

0

Surgery, chemotherapy

None

Complete

14

48/F

Rectal cancer

Recurrent

0

Surgery, chemotherapy, radiation therapy

None

Complete

  1. ECOG Eastern Coorperative Oncology Group, PS performance status
  2. aTwo patients were excluded from trial because the purity (no. 1) or the number (no. 2) of expanded cells didn’t exceed eligible value